Distribusion Technologies | $80,000,000 | (Sep 27, 2024)
Cytix | $2,143,528 | (Sep 27, 2024)
Convergence | $12,000,000 | (Sep 27, 2024)
Mogrify
United Kingdom
- Cambridge, Cambridgeshire
- 03/10/2023
- Series A
- $10,000,000
Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems, 2020).
The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type.
Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease.
Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications.
Based in Cambridge, UK, the Company has raised over $40 million USD funding from Parkwalk, Ahren Innovation Capital, 24Haymarket, Trend Investment Group, Dr. Darrin M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management.
- Industry Biotechnology
- Website http://www.mogrify.co.uk/
- LinkedIn https://www.linkedin.com/company/mogrify-reprogramming-health/about/
Related People
Darrin M Disley OBEFounder
United Kingdom -
Cambridge, England
Have started, grown and/or invested in >40 life science, technology and social enterprises closing c$600M financing and c$700M in commercial deals. Follow on Twitter @DarrinMDisley
Currently CEO of and Investor in Mogrify Ltd a pre-clinical stage biotechnology company developing a pipeline of in vivo reprogramming therapies that address chronic diseases of ageing using a systematic direct cell conversion & maintenance platform powered by big-data. Follow on Twitter @Mogrify_UK
Also Chairman of and investor in Celixir Ltd a clinical stage biotechnology company founded by Nobel Laureate Sir Martin Evans who are developing cell therapies for cardiovascular, oncology and orthopaedic indications.
Previously was co-founder, investor and former CEO of gene editing company Horizon Discovery Group Plc (LSE: HZD) leading company from $200k seed-funding to a 2.5X oversubscribed $113M life science IPO on AIM and onto a peak market capitalization in excess of $550M returning 2 to 50X ROI.
Avid believer in developing entrepreneurial talent supporting business plan competition and providing non-dilutive funding and mentoring programs via a 10-year endowment of the C R Lowe Carpe Diem Enterprise Fund. Projects supported recently include Cambridge University Entrepreneurs, HealX Ltd, Footprint Cafes CIO, MPhil in Bioscience Enterprise (Cambridge University) and SimPrints Ltd.
Recognition (selected):
Officer of the Most Excellent Order of the British Empire
Lifetime Queens Award for Enterprise Promotion
European Life Science Business Leader of the Year
UK Quoted Company Entrepreneur of Year
UK Public Life Science CEO of Year
Barclays Iconic UK Male Entrepreneur
Scrip Awards
Best Licensing Deal
Executive of Year
Business Excellence Awards
Business Person of Year
Times/Maserati 100 Disruptive UK Entrepreneurs
Cambridge's 25 Most Influential
100 Faces of a Vibrant UK Economy
Royal Society of Chemistry
175 Faces of Chemistry
SURGAR | $12,288,870 | (Sep 27, 2024)
Quorum | Undisclosed Amount | (Sep 27, 2024)
Prepared | $27,000,000 | (Sep 27, 2024)
AmpUp | $15,000,000 | (Sep 27, 2024)
HighFive | $250,000 | (Sep 27, 2024)
Tetrix | $5,000,000 | (Sep 27, 2024)
The Curling Group | $5,000,000 | (Sep 27, 2024)
AminoChain | $5,000,000 | (Sep 27, 2024)
Gladly | $40,000,000 | (Sep 27, 2024)